New medications show promise for migraine sufferers.
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008274:Magnesium / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D009465:Neuromuscular Agents / Q000627:therapeutic use; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D012256:Riboflavin / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D020903:Tanacetum parthenium; D014363:Tryptamines
D002227:Carbazoles; D007211:Indoles; D009465:Neuromuscular Agents; D028321:Plant Preparations; D011759:Pyrrolidines; D012702:Serotonin Antagonists; D014363:Tryptamines; C409045:almotriptan; C115647:eletriptan; D019274:Botulinum Toxins, Type A; C108128:frovatriptan; D008274:Magnesium; D012256:Riboflavin